Yes, I agree StephenB.This one is probably worth watching.After...

Yes, I agree StephenB.
This one is probably worth watching.
After some weakness, it is now back to its pre-covid level.
Probably due to the fact that they seem to have passed the bottom for their cold/flu products.

Good also to see that 2 directors are buying on the market, even if it does not offset what the CEO has been selling recently.

Valuation looks also interesting with a free cash flow yield of 8 % based on H1 22 annualised (including lease in total debt).
Good if they are able to go back to their organic growth pre-covid (around 10 % if I remember well).
During H1 22, their organic growth was still weak with proforma revenue growth of only 3 %.

The market may wait for the next update before deciding a new re-rating for this company.